Results 161 to 170 of about 25,328 (173)

Role of Consolidation Durvalumab in Patients With EGFR- and HER2-Mutant Unresectable Stage III NSCLC

Journal of Thoracic Oncology, 2021
Millie Das, Sukhmani K Padda, Kavitha Ramchandran   +2 more
exaly  

A Cost-Effectiveness Analysis of Consolidation Immunotherapy With Durvalumab in Stage III NSCLC Responding to Definitive Radiochemotherapy in Switzerland

Annals of Oncology, 2020
Daniel M Aebersold, L Plasswilm, D M Aebersold   +2 more
exaly  

De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancer

European Journal of Cancer, 2022
Michael Kelley, Drew Moghanaki, Lili Zhao   +2 more
exaly  

Durvalumab Consolidation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer With Driver Genomic Alterations

European Journal of Cancer, 2022
Edouard Auclin, Marco Tagliamento, Roxana Reyes   +2 more
exaly  

Outcomes With Durvalumab by Tumour PD-L1 Expression in Unresectable, Stage III Non-Small-Cell Lung Cancer in the PACIFIC Trial

Annals of Oncology, 2020
Luis Paz-Ares, Mustafa Özgüroğlu, Suresh Senan   +2 more
exaly  

NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC

Journal of Thoracic Oncology, 2023
Nick Syrigos, Gilberto de Castro, Urban Scheuring   +2 more
exaly  

Durvalumab

Reactions Weekly, 2018
openaire   +1 more source

A Randomised Phase II Study Investigating Durvalumab in Addition to an Anthracycline Taxane-Based Neoadjuvant Therapy in Early Triple-Negative Breast Cancer: Clinical Results and Biomarker Analysis of GeparNuevo Study

Annals of Oncology, 2019
Sherko Kuemmel, J-U Blohmer, P A Fasching   +2 more
exaly  

Durvalumab Plus Platinum–Etoposide Versus Platinum–Etoposide in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (CASPIAN): A Randomised, Controlled, Open-Label, Phase 3 Trial

Lancet, The, 2019
Michael Studnicka, Nikolay V Conev
exaly  

Four-Year Overall Survival Update From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma

Annals of Oncology
Vincent C Tam, Michael Paskow, Yoshiyuki Takei   +2 more
exaly